XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
NCT07688577
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Advanced Solid Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Xilio Development, Inc.
- Last updated on ClinicalTrials.gov
- November 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Ohio · 1
- Investigator Site · Canton, OH
Texas · 1
- Investigator Site · Fort Worth, TX
Virginia · 1
- Investigator Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.